Document is current
Any future updates will be listed below
-
Authors
Hatoum, Alexander S. https://orcid.org/0000-0002-8002-7267
Gorelik, Aaron J.
Blaydon, Lauren
Huggett, Spencer B.
Chi, Tingying
Baranger, David A. A. https://orcid.org/0000-0002-6659-357X
Miller, Alex P. https://orcid.org/0000-0001-9163-8947
Johnson, Emma C. https://orcid.org/0000-0003-0394-777X
Agrawal, Arpana https://orcid.org/0000-0002-0313-793X
Bogdan, Ryan
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (AA030083)
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 22 April 2025
First Online: 16 May 2025
Competing interests
: Spencer B. Huggett is an employee of HiFi Bio and sole owner of SYNAPZE LLC. He was not employed by HiFiBiO Therapeutics or SYNAPZE LLC during his work on this project. HiFiBiO Therapeutics had no role in the analysis, and no technology or supplies from their company were used herein. Alexander S. Hatoum and Spencer B. Huggett are listed as inventors on two preliminary patents related to these analyses, T-020521—Treatments for multi-drug or broad addiction liability, and T-020507 Multi-omics algorithm for testing neurological and psychiatric pharmaceutical efficacy. All other authors declare no competing interest.
: Spencer B. Huggett is the owner of Synapze LLC. Synapze LLC had no role in the analysis, and no technology or supplies from their companies were used herein. Alexander S. Hatoum and Spencer B. Huggett are listed as inventors on two preliminary patents related to these analyses, T-020521—“Treatments for multi-drug or broad addiction liability”, and T-020507 “Multi-omics algorithm for testing neurological and psychiatric pharmaceutical efficacy”.
